CJC-1295 vs GHK-Cu
Side-by-Side Comparison
| Attribute | Cjc 1295 | Ghk Cu |
|---|---|---|
| Category | Growth Hormone Secretagogue | Skin & Tissue Repair |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. |
| Evidence Rating | D — Preclinical | F — No Regulatory Activity |
| Clinical Status | Research-only / Not approved for human use | Available in cosmetic formulations; no drug approval |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520); Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin |
| Route | Subcutaneous | Subcutaneous, Topical (cream/serum), or Intradermal (microneedling) |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | SC: Once daily; Topical: 1–2x daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~403.9 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~30 minutes plasma |
Overview
CJC-1295 and GHK-Cu are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
GHK-Cu — Mechanism & Evidence
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.
Key claims: Improves skin firmness and elasticity; Promotes wound healing; Reduces fine lines and wrinkles.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
CJC-1295 is also researched for: Body Composition.
GHK-Cu is also researched for: Skin Health, Wound Healing.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520) Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
GHK-Cu: Copper Peptide in Tissue Repair and Skin Research
GHK-Cu, or glycyl-L-histidyl-L-lysine copper complex, stands out as a naturally occurring peptide central to human tissue maintenance and repair. Found in plasma, saliva, urine, and skin, its levels drop from about 200 ng/mL in young adults with age, linking to reduced regeneration. Preclinical studies highlight its roles in collagen production, wound healing, angiogenesis, anti-inflammation, and more, with the copper complex showing greater potency than unbound GHK.